Point-Counterpoint: Oncotype Dx Genomic Prostate Score in Active Surveillance – Canary PASS Study
Daniel W. Lin, MD, and Eric A. Klein, MD, present a point-counterpoint on the conclusions of Dr. Lin’s recently published results of Canary PASS (Prostate Active Surveillance Study), which looked at the ability of the Oncotype DX genomic prostate score (GPS) for predicting adverse pathology (AP) in primarily low-risk prostate cancer patients undergoing active surveillance. Following each presentation, Dr. Lin and Dr. Klein also discuss several follow-up questions related to the study and, more broadly, the future of prostate cancer treatment with E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology.
Read More